Immuneering Advances Atebimetinib in Pancreatic Cancer
NEW YORK – August 26, 2026 Immuneering Corporation (Nasdaq: IMRX) highlighted its continued focus on first-line metastatic pancreatic cancer...
metastatic pancreatic cancer
Advertisement
AIM ImmunoTech Advances Ampligen Toward Phase 3 Cancer Trial
OCALA, Fla., August 10, 2026 AIM ImmunoTech Inc. reported its second-quarter 2026 financial results and highlighted continued progress in...
CervoMed Secures UK ILAP Innovation Passport for Neflamapimod
BOSTON, Aug. 4, 2026 CervoMed Inc. announced that its investigational oral therapy neflamapimod has been granted an Innovation Passport...
AIM ImmunoTech Advances DURIPANC Trial with Final Dosing Milestone
OCALA, Fla., Aug. 3, 2026 AIM ImmunoTech Inc. announced that the final patient has received the last protocol-defined dose...
Revolution Medicines Reports Promising Phase 1/2 Zoldonrasib Combination Data in Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., July 2, 2026 Revolution Medicines announced encouraging Phase 1/2 clinical results for its investigational RAS(ON) G12D-selective...
Advertisements
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment
Ocala, Florida | June 18, 2026 AIM ImmunoTech Inc. announced that the final patient has received the first dose...
Verastem Oncology Shows Encouraging Survival Data in RAMP 205 Pancreatic Cancer Trial
BOSTON, June 17, 2026 Verastem Oncology announced positive updated safety and efficacy findings from the Phase 1b/2a RAMP 205...
Verastem Oncology Doses First Patient in TARGET-D 201 Trial
BOSTON, June 16, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 201 Phase...
Wockhardt’s ZAYNICH Wins FDA Approval for Drug-Resistant cUTIs
MUMBAI, India & SHORT HILLS, N.J., May 30, 2026 Wockhardt has achieved a historic milestone with the U.S. Food...
Bristol Myers Squibb Camzyos Gains FDA Priority Review
PRINCETON, N.J., June 1, 2026 Bristol Myers Squibb has achieved a significant regulatory milestone after the U.S. Food and...
Advertisement
